About Me and Deals

About Me - My Background and Dealsheet

Strong industry knowledge, extensive contacts, deal experience, and enthusiasm.

After working for a variety of biotech and pharma companies for over 20 years and accumulating a vast variety of experiences, I started Pullan Consulting, to provide business development to biotechnology and pharmaceutical companies.

My extensive contacts (>2400 read Pullan's Pieces), my deal experience, and my understanding of how big pharma operates, are available to help you make your deal happen.

I understand both sides, the small company innovation and the big company depth of resources and expertise in drug discovery, clinical development and commercialization.

My track record of closed deals ranging from up to $100 million upfront sets the ideal frame for your deal making opportunities.

What counts for me is the candor and enthusiasm necessary to successfully manage deals and licensing for businesses of any size. I won't say "no" to small jobs if I think I can contribute.

My Background

VP of Business Development at Kosan Biosciences,

Responsible for all business development activities, strategy, market analysis, financial models, messaging, relationship management and negotiations

Head of Oncology and Hematology Licensing at Amgen,

Created and led licensing team of 10 (including legal and finance) for Amgen's biggest therapeutic areas, oncology and hematology

Collaborations Manager at what is now AstraZeneca Pharmaceuticals,

Led identification, evaluation and negotiations of academic and industry research collaborations

Drug Discovery Research at what is now AstraZenecan and Pfizer.

Led teams and contributed to 3 drugs entering the clinic; 1 now >$1B in sales.

55 publications.

Ph.D. in Biochemistry and a B.S. in Chemistry.

Deals Sheet

As a consultant, I've worked on ~8 signed deals so far, with upfronts ranging from $300K to $30M.

Strategic Alliances (>$50MM upfront)

Client- Big Pharma: $30MM upfront, big chemistry collaboration.
Tularik -Amgen: $125MM upfront,
targets and drug development, led evaluation team, launched collaboration that led to acquisition

Praecis - Amgen: $100MM upfront,
Ph 3 GnRH antagonist, led evaluation team

Immunomedics - Amgen: $65MM upfront, Ph 2/3 NHL Ab, led evaluation team and member of negotiation team

Abgenix - Amgen: multi-antigen Ab creation, supervised evaluator and negotiator

Medarex - Amgen: multi-antigen Ab creation, supervised evaluator and negotiator

Kinetix acquisition - Amgen: $170MM upfront, kinases and structural biology, led evaluation and diligence

Mid-Size Deals (>$10M)

Client - Big pharma: preclinical drug candidate, modeled, negotiated
Client- Biotech: preclinical drug candidate, made contact, modeled, negotiated
Client- Big pharma: discovery collaboration, modeled, helped negotiate behind the scences
Client - biotech: discovery collaboration, pushed for and got higher value than expected
Client- pharma: option deal, led negotiations
Vanderbilt - Amgen: preclinical Ab, led negotiation

Biosite - Amgen: multiple Abs, supervised evaluator and negotiator

Incyte - Zeneca: genomics database, on negotiation team

Pharmacopeia - Zeneca: combinatorial chemistry, on negotiation team

U C Irvine - Zeneca: lead optimization ion channels, led evaluation and negotiations

U College of London - Zeneca:
small molecule lead, led renegotiations

Smaller Deals

Client- university: in-licensing, adviced on deal concepts critical to sublicense to big pharma
Dako - Amgen: companion diagnostic development, supervised evaluator, led negotiations

Ventana - Amgen: companion diagnostic development, supervised evaluator, led negotiations

Skye Pharma - Amgen: drug delivery, led evaluation and negotiations

Many biomarker deals: supervisory roles

Many IP licenses: negotiator and supervisory roles

Pullan Consulting

Biotech Business Development lpullan@msn.com 805-558-0361